{"id":"W3044214090","doi":"10.1016/j.clon.2020.07.006","title":"Optimising the Duration of Adjuvant Trastuzumab in Early Breast Cancer in the UK","year":2020,"lang":"en","type":"editorial","venue":"Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Daiichi Sankyo Company; National Institute on Handicapped Research; Merck Sharp and Dohme; Health Technology Assessment Programme; Eisai; AstraZeneca France; Daiichi-Sankyo; National Institute for Health and Care Research; Puma Biotechnology; Les Laboratories Pierre Fabre; Genomic Health; Elsevier Foundation; Sanofi; Novartis; Celgene; Roche; Oncolytics Biotech; Cancer Research UK; Intas Pharmaceuticals; Department for Culture, Heritage and the Gaeltacht, Ireland; Amgen; Novartis Pharmaceuticals Corporation; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Trastuzumab; Neratinib; Breast cancer; Internal medicine; Adjuvant therapy; Adjuvant; Cancer; Surgery; Oncology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01479275,0.002956422,0.003905209,0.002495716,0.001676104,0.007766252,0.003366032,0.02013481,0.01193574],"category_scores_gemma":[0.05008215,0.001232471,0.002872699,0.001448432,0.002442809,0.004930313,0.001578393,0.02540037,0.00609141],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.007247447,"about_ca_system_score_gemma":0.005805435,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004467625,"about_ca_topic_score_gemma":0.01047571,"domain_scores_codex":[0.9920464,0.002120023,0.00133904,0.0007148893,0.003215114,0.0005645158],"domain_scores_gemma":[0.9531182,0.02787278,0.002958392,0.0005796344,0.01035426,0.005116727],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001950945,0.00001855857,0.00003157468,0.0007288976,0.00005740333,0.0001032399,0.00002172038,0.00008215937,0.00008159778,0.0007299117,0.983911,0.01403887],"study_design_scores_gemma":[0.0004048284,0.0001730982,0.0006381097,0.001782348,0.0002765421,0.0002501072,0.00008439592,0.0002849134,0.0001849759,0.00201505,0.9938546,0.00005111101],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"editorial","genre_gemma":"editorial","genre_scores_codex":[0.00006636931,0.01925385,0.0001451386,0.07796603,0.9007645,0.00002574985,0.00007237153,0.0000391152,0.001666826],"genre_scores_gemma":[0.0009542009,0.01518419,0.0001312578,0.03565062,0.9423421,0.00003321112,0.00002892077,0.00003398431,0.005641483],"genre_candidate":"editorial","genre_consensus":"editorial","teacher_disagreement_score":0.02013481,"threshold_uncertainty_score":0.07823253,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1272786951343438,"score_gpt":0.5247389173070323,"score_spread":0.3974602221726884,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}